Catheter Precision, Inc. Announces First Use of VIVO in Qatar

Catheter Precision, Inc. (NYSE American:VTAK), a medical device company based in the U.S., recently reported the inaugural use of its VIVO device in Qatar. The procedures were carried out at Hamad Medical Corporation Heart Hospital in Doha, marking VIVO's first application in the Middle East. Hamad Medical Corporation, the premier provider of secondary and tertiary healthcare in Qatar and a leading entity in the region, comprises 12 hospitals.

David Jenkins, CEO of Catheter Precision, expressed satisfaction with the initial use of VIVO in Doha, noting the physician's positive feedback regarding the device's accuracy. The company aims to expand its presence in the Middle East and demonstrate VIVO's benefits in new territories. VIVO, designed to identify the origin of ventricular arrhythmias non-invasively, has been cleared by the U.S. FDA and holds the CE mark, endorsing its application in electrophysiology procedures.

The communication also issued caution regarding forward-looking statements, citing numerous factors that might influence actual results, including market acceptance, regulatory requirements, operational risks, and the potential impact of external factors such as the COVID-19 pandemic and global trade changes.